Company

Apogenix is a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases. The compound´s mechanism of action is either based on the targeted modulation of the programmed cell death (a.k.a. apoptosis - ἁπόπτωσισ is used in Greek to describe the "falling off" of leaves from trees) or on the inhibition of tumour cell growth. The lead product candidate of the company, APG101, is currently in a controlled phase II proof of concept study with GBM patients (GBM: Glioblastoma multiforme). The primary endpoint of this study has been met. Data on secondary endpoints will become available in the next months.

Apogenix was founded as a spin-out from the German Cancer Research Center (DKFZ). Since its inception in fall 2005, the company has raised more than € 50 million in three financing rounds. In addition, the company has been awarded public funds totalling nearly € 8.5 million of which almost € 5 million have been granted as part of the so-called “Spitzencluster-Wettbewerb” initiated by the German Ministry for Research and Education (BMBF). Apogenix is based in Heidelberg, Germany, and currently employs some 25 people.